Researchers from the University of Otago have uncovered another possible clue that could help scientists identify Alzheimer’s disease much earlier than before.
Their findings suggest that changes linked to Alzheimer’s may begin decades before doctors can detect obvious memory loss or major brain damage.
The study used information from the famous Dunedin Multidisciplinary Health and Development Study, one of the world’s longest-running health studies. The research followed people from childhood into adulthood and collected detailed health information over many decades.
The new findings were published in the scientific journal GeroScience.
Alzheimer’s disease is the most common cause of dementia worldwide. It slowly damages memory, thinking, reasoning, and behavior. As the disease progresses, people may struggle with daily tasks, recognizing loved ones, or living independently. The condition places a huge emotional and financial burden on families and healthcare systems around the world.
Scientists have spent years trying to understand when Alzheimer’s truly begins. Traditionally, the disease is diagnosed after memory problems and brain changes become severe enough to affect everyday life. However, many researchers now believe the disease process may quietly start many years earlier.
In this new study, researchers focused on a blood biomarker known as ptau181. Biomarkers are measurable substances in the body that may signal disease or health changes. Earlier studies have already linked high levels of ptau181 to Alzheimer’s disease in older adults.
The researchers wanted to know whether signs of this biomarker could already be found much earlier in life, even before major symptoms appeared.
As part of the Dunedin Study’s age-45 assessments, participants answered questions about their memory and thinking abilities. They also completed detailed cognitive tests designed to measure attention, memory, learning, and mental processing skills.
Researchers then used MRI brain scans and special aging tools called DunedinPACE to examine brain structure and biological aging.
The results showed that people with higher levels of the ptau181 biomarker were more likely to report concerns about their memory and thinking. Some participants felt they were becoming more forgetful or mentally slower even though formal brain scans did not yet show measurable structural changes.
Lead researcher entity[“people”,”Ashleigh Barrett-Young”,”psychology researcher”] explained that the findings suggest subtle changes in thinking may happen before doctors can detect visible damage in the brain.
This may be important because it supports the growing idea that Alzheimer’s-related changes start developing very early, possibly decades before the disease is officially diagnosed.
Scientists believe this early period could become a critical opportunity for prevention. If doctors can identify high-risk individuals before major brain damage occurs, future treatments or lifestyle changes may help delay or reduce disease progression.
Researchers stress that the study does not mean everyone with elevated ptau181 will definitely develop Alzheimer’s disease. Biomarkers indicate risk, not certainty. Many factors influence whether someone eventually develops dementia, including genetics, health conditions, lifestyle, education, and overall aging.
Currently, blood tests for Alzheimer’s biomarkers are still mostly used in research settings and are not widely available for routine medical use in New Zealand or many other countries. However, experts believe blood-based testing could eventually become a simpler and more affordable way to identify people at higher risk.
Compared with expensive brain scans or spinal fluid testing, blood tests would be easier to use in large populations and could help doctors identify patients earlier.
The research also highlights how difficult it can be to detect the earliest stages of Alzheimer’s disease. Although participants reported concerns about their memory, MRI scans still showed no clear structural brain damage at age 45.
This suggests the disease process may involve very subtle biological changes long before standard medical tools can identify obvious problems.
The Dunedin Study continues to receive international attention because it follows the same group of people over their entire lives. Scientists believe this type of long-term research is extremely valuable for understanding aging and disease development.
entity[“people”,”Moana Theodore”,”research professor”], Director of the Dunedin Study, praised the work and emphasized the important role New Zealand researchers are playing in global aging research.
She also highlighted the commitment of the study participants, who continue contributing their time and personal information to help scientists better understand aging and disease.
Many participants have personally witnessed how dementia affects families and communities. Researchers say their willingness to participate may help future generations benefit from earlier detection and improved treatments.
The findings come at a time when Alzheimer’s disease is becoming a major global health challenge. As populations age, the number of dementia cases is expected to rise sharply in coming decades. Scientists worldwide are urgently searching for ways to diagnose and prevent the disease earlier.
Reviewing the study findings, the research appears highly valuable because it strengthens evidence that Alzheimer’s disease may begin developing long before major symptoms or visible brain damage appear. The study’s use of a large, long-term population group adds credibility to the findings.
However, researchers still do not know exactly how elevated ptau181 levels relate to future dementia risk over many decades. More research will be needed before blood biomarker testing becomes part of routine healthcare.
Even so, the study offers hope that earlier detection and prevention strategies may eventually reduce the devastating impact of Alzheimer’s disease worldwide.
If you care about Alzheimer’s disease, please read studies about the protective power of dietary antioxidants against Alzheimer’s, and eating habits linked to higher Alzheimer’s risk.
For more health information, please see recent studies that oral cannabis extract may help reduce Alzheimer’s symptoms, and Vitamin E may help prevent Parkinson’s disease.
Source: University of Otago.
